J.P. Morgan Healthcare Conference 2010, San Francisco, January 11-14; biotuesdays.com Will Be There

J.P. Morgan’s 28th Annual Healthcare Conference, is being held January 11-14, 2010 at the Westin St. Francis in San Francisco.   This event is the premier conference of its kind,with more than 300 companies, both public and private, delivering presentations to more than 3,500 investors.  There is even more (much more) activity outside of the official [...]

Miraculins inks deal with IMA to develop test for preeclampsia

Winnipeg-based Miraculins (TSXV:MOM) has entered into a partnership with Inverness Medical Innovations (NYSE:IMA) of Waltham, Mass. to advance and commercialize Miraculins’ preeclampsia technology. The technology is based on a suite of 35 novel biomarkers involved in the development of the placenta and the biology implicated in the development of preeclampsia, a debilitating and potentially fatal [...]

Ondine files PMA for Periowave with FDA

Ondine Biopharma (TSX:OBP) has filed a premarket approval submission with the FDA for marketing approval in the U.S. of the Periowave photodisinfection system to treat chronic periodontitis in adults, as an adjunct to standard methods of care. “The PMA submission represents a major milestone for Ondine and our business partner, Periowave Dental Technologies,” Ondine CEO [...]

Resverlogix redeems debentures

Resverlogix (TSX:RVX) has completed the previously announced redemption of all outstanding convertible notes 2.5 years ahead to maturity. In a statement, the company said a total of $6,728,000 (U.S.) of convertible debt, due June 6, 2012, has been redeemed. The redemption follows moves in December for a $5-million (Canadian) equity private placement and a standby [...]

Amorfix names Gundel as VP of R&D

Amorfix Life Sciences (TSX:AMF) has appointed 25-year drug development veteran Dr. Robert Gundel as vice president of research and development. “Robert’s extensive record of new product advancement will be a great asset as we continue to discover, develop and commercialize novel diagnostic and therapeutic products based on our Epitope Protection and ProMIS technology platforms,” Dr. [...]

ProMetic in development accord with Abraxis

ProMetic Life Sciences (TSX:PLI) and Abraxis BioScience (NASDAQ: ABII) of Los Angeles have entered into a collaboration agreement to develop and commercialize various applications using ProMetic’s prion capture technology platform to improve the safety profile of blood-derived therapeutics. Under the accord, both companies will equally share the cost for the development of new applications as well [...]

Cipher plans to license-in new drug this year

For much of its six years as a separate company, Cipher Pharmaceuticals (TSX:DND) has been known for driving its three drugs toward the finish line.  That could change in 2010. “We ramped up our in-house resources last year to look at adding pipeline opportunities, and we’ve looked at over 100 to this stage,” CEO Larry Andrews [...]

« Previous Page